Alexandra Traverse‐Glehen
A5004594498- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- T-cell and Retrovirus Studies
- CAR-T cell therapy research
- Cutaneous lymphoproliferative disorders research
- Lung Cancer Treatments and Mutations
- Cytomegalovirus and herpesvirus research
- Breast Implant and Reconstruction
- Cardiac tumors and thrombi
- Diabetes and associated disorders
- Acute Lymphoblastic Leukemia research
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Eosinophilic Disorders and Syndromes
- Fungal Infections and Studies
- Cancer-related gene regulation
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- T-cell and B-cell Immunology
Centre de Recherche en Cancérologie de Lyon
2016-2025
Université Claude Bernard Lyon 1
2016-2025
Hospices Civils de Lyon
2016-2025
Hôpital Lyon Sud
2016-2025
Centre National de la Recherche Scientifique
2015-2025
Inserm
2016-2025
Université de Rouen Normandie
2024
Normandie Université
2024
Centre Henri Becquerel
2024
Centre International de Recherche en Infectiologie
2022-2023
ALK-negative anaplastic large cell lymphoma associated with breast implant (i-ALCL) has been recently recognized as a distinct entity. Among 43 830 lymphomas registered in the French Lymphopath network since 2010, 300 comprising 25 peripheral T-cell (PTCL) were reviewed. PTCL, ALCL was most frequent and all of them implants.Since i-ALCL cases collected from different institutions through Lymphopath. Immuno-morphologic features, molecular data clinical outcome 19 i-ALCLs have retrospectively...
Purpose Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known their causes death (CODs) in rituximab era. Patients and Methods We pooled two cohorts newly diagnosed FL grade 1-3A. were enrolled between 2001 2013 French referral institutions (N = 734; median follow-up 89 months) 2002 2012 University Iowa Mayo Clinic Specialized Program Research Excellence (SPORE; N 920; 84 months). COD was classified as being a result lymphoma, other malignancy,...
Purpose To prospectively assess the clinical impact of expert review lymphoma diagnosis in France. Materials and Methods From January 2010 to December 2013, 42,145 samples from patients with newly diagnosed or suspected lymphomas were reviewed, according 2008 WHO classification, real time by experts through Lymphopath Network. Changes between referral classified as major minor their potential on patient care. Results The reviewed comprised 36,920 mature lymphomas, 321 precursor lymphoid...
In recent years, overlap in biologic and morphologic features has been identified between classic Hodgkin lymphoma (cHL) B-cell non-Hodgkin lymphoma. Nevertheless, the therapeutic approaches for these diseases remain different. We undertook a study of "mediastinal gray zone lymphomas" (MGZL), with transitional cHL nodular sclerosis (NS) primary mediastinal large (MLBCL) to better understand immunophenotypic spectrum such cases. Twenty-one MGZL cases were over 20-year period. also studied 6...
Abstract Anti‐PD‐1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti‐PD‐1 not well known. We retrospectively investigated the salvage therapies for unsatisfactory therapy, assessed by PET‐CT according Lugano criteria, 30 R/R HL patients. Patients were...
Primary mediastinal B‐cell lymphoma (PMBL) is an entity of distinct from the other molecular subtypes diffuse large (DLBCL). We investigated prevalence, specificity, and clinical relevance mutations XPO1 , which encodes a member karyopherin‐β nuclear transporters, in cohort PMBL. PMBL cases defined histologically or by gene expression profiling (GEP) were sequenced mutational status was correlated to genetic characteristics. The also assessed DLBCL, Hodgkin (HL) gray‐zone (MGZL).The...
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways surrounding microenvironments diverse. We sought to clarify the heterogeneity of SMZL by resolving different subgroups their underlying genomic abnormalities, pathway signatures, microenvironment compositions uncover biomarkers therapeutic vulnerabilities. studied 303 spleen samples...
Abstract Burkitt lymphoma (BL) accounts for most pediatric non-Hodgkin lymphomas, being less common but significantly more lethal when diagnosed in adults. Much of the knowledge genetics BL thus far has originated from study (pBL), leaving its relationship to adult (aBL) and other lymphomas not fully explored. We sought thoroughly identify somatic changes that underlie lymphomagenesis aBL any molecular features associate with clinical disparities within between pBL aBL. Through comprehensive...
The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (BV-AVD) in previously untreated, (ClinicalTrials.gov identifier: NCT02292979). BREACH is a multicenter, randomized, open-label, phase II trial. Eligible were age 18-60 years ≥ 1 EORTC/LYSA criterion. Patients randomly assigned (2:1) to four cycles BV-AVD or standard bleomycin, vincristine, (ABVD),...
Background Classically, splenic marginal zone B-cell lymphoma is characterized by the absence of CD5 expression. Cases apparent showing expression, as diagnosed blood studies, have been described; however, in histological evidence, correct diagnosis these cases controversial because possible confusion with other CD5-positive small neoplasms.Design and Methods We report a series 24 CD5-positive, t(11;14)-negative flow cytometry studies histologically proven on spleen sections. Clinical data...
Splenectomy is considered as one of the first-line treatments for symptomatic patients with splenic marginal zone lymphoma (SMZL). Between 1997 and 2012, 100 hepatitis C virus-negative SMZL were treated by splenectomy treatment. At 6 months, all but three recovered from cytopenias. The median lymphocyte count at months 1 year was 11.51 × 109/L 6.9 109/L, respectively. Median progression-free survival (PFS) 8.25 years. 5-year 10-year overall (OS) rates 84% 67%, Histological transformation...